11. CONFLICT OF INTEREST
All members of the Renal Cell Cancer Guidelines Panel have provided disclosure statements of all
relationships that they have that might be perceived as a potential source of a conflict of interest. This information is published below and also publicly accessible through the European Association of Urology website: https://uroweb.org/guideline/renalcellcarcinoma/panel.
This Guidelines document was developed with the financial support of the European Association of Urology. No external sources of funding and support have been involved. The EAU is a non-profit organisation, and funding is limited to administrative and travel and meeting expenses. No honoraria or other reimbursements have been provided.
Disclosures: The EAU Guidelines Office certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/ affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: A. Bex reported receiving research support and grants from Pfizer; a trial participant for Roche/Genentech and BMS and a company consultant for Ipsen. J. Bedke reported serving as a company consultant for Astella, AstraZeneca, BMS, Eisai, Ipsen, Janssen, Merck Sorono, MSD, Pfizer and Roche; receiving company speaker honoraria from Ispen Pharma GMBh, BMS, MSD, Pfizer and Seagen; declares trial participation with Astella, AstraZeneca, BMS, Eisai, Ipsen, MSD, Nektar, Novartis, Pfizer, Roche and Seagen and receiving honoraria from Ipsen. U. Capitanio reported receiving consultation fees from MSD Italia srl and serving as company speaker and receiving fellowship and travel grants from Merck Sharp & Dohme S.p.A. S. Dabestani reported serving as a company consultant for Elypta AB. M. Hora reported serving as a company consultant for MSD, receiving company speaker honorarium from MSD and consultation fees from Merck Spol. S.R.O. G. Pignot reported receiving company speaker honoraria from Merck, AstraZeneca, Bouchara Recordati, Pfizer, Ipsen, J&J, Bayer, Bristol Myers Squibb and Astellas; receiving honoraria or consultation fees from AstraZeneca, Bayer, J&J and Intuitive Surgical; and participating in clinical trials with J&J and Vitadx International. M. Tran received research support from Boston Scientific and honoraria, consultation fees from Boston Scientific, Eisai Europe Ltd, Telix Pharmaceuticals and Merck Sharp & Dohme. R. Campi received consultation fees from Telix pharmaceuticals and Nucleix; fellowship, travel grants from MSD Italia srl. T. Powles reported receiving honoraria or consultation fees from AstraZeneca, Astellas Pharma, Bristol Myers Squibb, Eisai Europe Ltd, Exelixis, Inc, F. Hoffmann-La Roche Ltd, Incyte Biosciences, Ipsen, Merck & Co Inc, Merck KGaA, Merck Sharp & Dohme, Merck Sharp & Dohme LLC, MSD Sharp & Dohme GmbH, Novartis Pharma AG, Pfizer, and Seattle Genetics; receiving grants or research support from AstraZeneca, Astellas Pharma, Astellas Pharma US, Bristol Myers Squibb, Eisai Europe Ltd, Exelixis, Inc., F. Hoffmann-La Roche Ltd, Ipsen, Johnson & Johnson, Merck & Co. Inc., Merck KGaA, Merck Sharp & Dohme, Merck Sharp & Dohme LLC, Merck Sharp & Dohme International Services, Novartis Pharma AG, Pfizer and Seattle Genetics; and reporting other relationships with AstraZeneca, F. Hoffmann-La Roche Ltd, Ipsen, MSD Sharp & Dohme GmbH, Merck Sharp & Dohme LLC and Pfizer. T. Klatte reported receiving fellowship or travel grants from Bristol Myers Squibb and serving as company consultant for Bristol-Myers Squibb Germany, Medac GmbH and Merck Healthcare Germany GmbH. C. Suarez reported serving as a company consultant to Vall Hebron Institute of Oncology (VHIO). Riccardo Campi has had advisory roles and has received travel grants from Telix Pharmaceuticals and MSD. Patricia Zondervan reported serving as company consultant for Telix pharma and receiving travel grants from IPSEN, BMS and Pfizer. T. Kuusk reported receiving company speaker honoraria from Telix and served as an advisory role for Telix. S. Bonn, D. Breen, Y. Abu Ghanem, R. Woodward, C. Palumbo, L. Lund and L. Marconi all have nothing to declare.